Actinium Pharmaceuticals (NYSE:ATNM) Downgraded to Sell at StockNews.com

StockNews.com downgraded shares of Actinium Pharmaceuticals (NYSE:ATNM) from a hold rating to a sell rating in a research report report published on Monday.

ATNM has been the subject of several other research reports. Cantor Fitzgerald reaffirmed an overweight rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, April 30th. Stephens initiated coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They issued an overweight rating and a $25.00 price objective for the company. Finally, HC Wainwright reaffirmed a buy rating and set a $50.00 target price on shares of Actinium Pharmaceuticals in a research note on Friday, July 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $11.43.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM opened at $2.41 on Monday. The stock has a market capitalization of $71.78 million, a P/E ratio of -1.41 and a beta of 0.20. Actinium Pharmaceuticals has a 1-year low of $1.33 and a 1-year high of $10.24.

Actinium Pharmaceuticals (NYSE:ATNM) last released its earnings results on Monday, August 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.02. As a group, equities analysts forecast that Actinium Pharmaceuticals will post -1.57 EPS for the current year.

Institutional Trading of Actinium Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its holdings in Actinium Pharmaceuticals by 23.4% during the second quarter. Rhumbline Advisers now owns 39,656 shares of the company’s stock valued at $293,000 after buying an additional 7,525 shares in the last quarter. Sanders Morris Harris LLC acquired a new position in shares of Actinium Pharmaceuticals during the 1st quarter valued at about $78,000. Bank of New York Mellon Corp raised its stake in shares of Actinium Pharmaceuticals by 28.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after acquiring an additional 19,035 shares in the last quarter. Virtu Financial LLC lifted its holdings in Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after purchasing an additional 62,459 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Actinium Pharmaceuticals by 6.0% during the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after purchasing an additional 82,113 shares during the period. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.